Sandeep C Nema

age ~62

from Stoneham, MA

Get Report

Also known as:

Sandeep S Nema
Christine Busch Nema
Christine M Nema
Sanjie Nema
Sendeep Nema
P Nema
Nema Sandeep
Christine A
Christine Busch

Connected to:

Sandeep Nema Phones & Addresses

Stoneham, MA
343 Bach Ave, Saint Louis, MO 63122 • (314)9655415
Kirkwood, MO
1778 Timber Ridge Estates Ct, Ballwin, MO 63011 • (636)2734807 • (636)2734951
Grayslake, IL

Work

Company:

Pfizer
Jan 2006 to 2008
Position:

Senior director, pharmaceutical r and d, global biologics

Education

Degree:

Doctorates, Doctor of Philosophy
School / High School:

The University of Tennessee Health Science Center
1987 to 1992

Skills

Drug Development • Pharmaceutical Industry • Technology Transfer • Pharmaceutics • Biotechnology • Gmp • Drug Discovery • Ind • Formulation • Biopharmaceuticals • Glp • Regulatory Affairs • Life Sciences • Validation • Clinical Development • Fda • Pharmacokinetics • Capa • Medicinal Chemistry • Pharmacology • Drug Delivery • Analytical Chemistry • Immunology • Sop • Vaccines • Hplc • Change Control • Regulatory Submissions • Clinical Pharmacology • Gcp • Pharmacovigilance • Quality By Design • Pharmaceutical Research • Infectious Diseases • Medical Affairs • Clinical Trials • Parenteral • 21 Cfr Part 11 • Regulatory Requirements • Drug Design • Biomarkers • Good Laboratory Practice • Oncology • Lifesciences • Cro • Translational Medicine • Ctms • Toxicology • Corrective and Preventive Action

Industries

Pharmaceuticals

Resumes

Executive Director

view source

Location:

St, Louis, MO

Industry:

Pharmaceuticals

Work:

Pfizer Jan 2006 - 2008
Senior Director, Pharmaceutical R and D, Global Biologics
Pfizer Jan 2006 - 2008
Executive Director
Pfizer 2003 - 2005
Director, Pharmaceutical R and D, Global Biologics
Pfizer 1997 - 2003
Group Leader
Mallinckrodt Medical 1992 - 1997
Research Pharmacist

Education:

The University of Tennessee Health Science Center 1987 - 1992
Doctorates, Doctor of Philosophy Banaras Hindu University 1982 - 1986
Bachelors, Bachelor of Pharmacy

Skills:

Drug Development
Pharmaceutical Industry
Technology Transfer
Pharmaceutics
Biotechnology
Gmp
Drug Discovery
Ind
Formulation
Biopharmaceuticals
Glp
Regulatory Affairs
Life Sciences
Validation
Clinical Development
Fda
Pharmacokinetics
Capa
Medicinal Chemistry
Pharmacology
Drug Delivery
Analytical Chemistry
Immunology
Sop
Vaccines
Hplc
Change Control
Regulatory Submissions
Clinical Pharmacology
Gcp
Pharmacovigilance
Quality By Design
Pharmaceutical Research
Infectious Diseases
Medical Affairs
Clinical Trials
Parenteral
21 Cfr Part 11
Regulatory Requirements
Drug Design
Biomarkers
Good Laboratory Practice
Oncology
Lifesciences
Cro
Translational Medicine
Ctms
Toxicology
Corrective and Preventive Action

Us Patents

Reconstitutable Parenteral Composition
view source
US Patent:

7695736, Apr 13, 2010
Filed:

Apr 1, 2002
Appl. No.:

10/113281
Inventors:

Tugrul T. Kararli - Skokie IL, US
Sandeep Nema - Grayslake IL, US
Aziz Karim - Skokie IL, US
Assignee:

Pfizer Inc. - New York NY
International Classification:

A61K 9/14
US Classification:

424489
Abstract:

A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.

Oral Dosage Form Of A Sulfonamide Prodrug
view source
US Patent:

20030100595, May 29, 2003
Filed:

Nov 12, 2002
Appl. No.:

10/292682
Inventors:

Aziz Karim - Skokie IL, US
Sandeep Nema - Grayslake IL, US
Gary Ewing - Kalamazoo MI, US
International Classification:

A61K031/415
A61K031/365
US Classification:

514/406000, 514/471000
Abstract:

A pharmaceutical composition that is substantially free of water comprises at least one orally deliverable dosage unit comprising a therapeutically effective amount of a sulfonamide prodrug and, where the prodrug is readily degradable ex vivo, has means to inhibit such degradation prior to oral administration. Illustratively the prodrug is parecoxib or a water-soluble salt thereof, and the composition has means to inhibit conversion of the parecoxib to valdecoxib. A method of treating or preventing a COX-2 mediated disorder in a subject comprises (a) dissolving at least one dosage unit of such a composition in a pharmaceutically acceptable aqueous vehicle to form a solution, and (b) orally administering the solution to the subject before substantial precipitation of insoluble matter occurs in the solution.

Anti-Ctla-4 Antibody Compositions
view source
US Patent:

20090130119, May 21, 2009
Filed:

Mar 2, 2006
Appl. No.:

11/817894
Inventors:

Justin Abate - Chesterfield MO, US
Kevin Muthurania - Chesterfield MO, US
Sandeep Nema - Chesterfield MO, US
Satish Singh - Chesterfield MO, US
Carrie Elliott - Seattle WA, US
Tapan Das - Chesterfield MO, US
International Classification:

A61K 39/395
A61P 35/00
US Classification:

4241421, 4241731, 4241541
Abstract:

The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.

Stable Immunogenic Compositions Of Staphylococcus Aureus Antigens
view source
US Patent:

20130259896, Oct 3, 2013
Filed:

Dec 21, 2011
Appl. No.:

13/993887
Inventors:

Lakshmi Khandke - Nanuet NY, US
Akihisa Nonoyama - Apex NC, US
Tamara Shafer Hodge - Chesterfield MO, US
Sandeep Nema - Chesterfield MO, US
International Classification:

A61K 39/085
US Classification:

42419711, 4242431
Abstract:

The present invention is directed towards a lyophilized or reconstituted multi-antigen or multicomponent immunogenic composition comprising at least one antigen isolated from a staphylococcal bacterium, and methods of making the same.